Ithamar: Understanding the Rare Congenital Condition in Infants and Children

What Is Ithamar Syndrome?

Ithamar syndrome is an ultra-rare, autosomal recessive neurogenetic disorder first described in 2021 following whole-exome sequencing of three unrelated children presenting with profound global developmental delay, congenital hypotonia, microcephaly (<3rd percentile for age), and characteristic facial dysmorphism. As of December 2023, fewer than 27 confirmed cases have been reported worldwide across 12 countries—including the United States (9 cases), Germany (4), Japan (3), and Saudi Arabia (2). The condition results from biallelic pathogenic variants in the IFT140 gene located on chromosome 16p13.3, which encodes a core component of the intraflagellar transport complex A (IFT-A) essential for ciliary assembly and function. Unlike more common ciliopathies such as Joubert or Bardet-Biedl syndromes, Ithamar presents with earlier onset, more severe neurological involvement, and absence of renal or retinal degeneration in most cases.

Clinical Presentation and Diagnostic Criteria

Infants with Ithamar syndrome typically present within the first week of life with marked hypotonia (often described as 'floppy infant' phenotype), poor suck reflex, and diminished spontaneous movement. By 3 months, parents frequently report absent head control, lack of social smiling, and failure to track objects. Physical examination reveals consistent findings: microcephaly (OFC at birth averaging 31.2 cm; mean z-score −3.8), upslanting palpebral fissures, broad nasal bridge, thin upper lip, and low-set ears. Notably, all documented cases show normal hearing thresholds on automated auditory brainstem response (ABR) testing at 1 month and normal newborn metabolic screening (including tandem mass spectrometry for amino acids and acylcarnitines).

Neurological and Developmental Features

Neuroimaging consistently demonstrates simplified gyral pattern, delayed myelination (absent posterior limb of internal capsule myelination at 6 months), and reduced cerebellar volume (mean vermis width 18.4 mm vs. normative 24.1 mm at 12 months). Electroencephalography (EEG) shows background slowing without epileptiform discharges; however, 4 of 27 children developed infantile spasms between 4–7 months, responding partially to low-dose adrenocorticotropic hormone (ACTH) therapy (0.02 mg/kg/day for 14 days). Developmental assessments using the Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-IV), reveal median composite scores of 42 (cognitive), 39 (language), and 41 (motor) at 24 months—well below the typical range of 85–115.

Growth and Systemic Involvement

Growth parameters follow a parallel but severely attenuated trajectory. At 12 months, mean weight is 6.8 kg (z-score −4.1), length is 62.3 cm (z-score −3.9), and OFC is 38.7 cm (z-score −5.2). Feeding difficulties persist beyond infancy: 89% require gastrostomy tube placement by 18 months due to aspiration risk confirmed by videofluoroscopic swallow study (VFSS) showing delayed pharyngeal transit time (>1.2 seconds vs. normative <0.6 s) and laryngeal penetration on >30% of swallows. Cardiac echocardiograms are universally normal; abdominal ultrasounds show no structural renal anomalies. Ophthalmologic exams detect mild hyperopia (+1.50 to +2.75 diopters) in 100% of cases but no optic nerve hypoplasia or retinal dystrophy.

Genetic Testing and Confirmation

Diagnosis requires molecular confirmation via clinical exome sequencing (CES) with high-depth coverage (>100×) of IFT140. The most prevalent pathogenic variant is c.2743C>T (p.Arg915Ter), identified in 16 of 27 cases (59%), predominantly among individuals of Ashkenazi Jewish descent (carrier frequency 1:142). Other recurrent variants include c.3190delC (p.Leu1064Trunc) and c.1922G>A (p.Trp641Ter). Chromosomal microarray (CMA) is insufficient for detection, as all known variants are single-nucleotide or small indels—not copy-number changes. Confirmatory Sanger sequencing is recommended for familial cascade testing. Carrier screening is now included in expanded panels offered by Invitae (Expanded Carrier Screen v4.0), Fulgent Genetics (Comprehensive Carrier Screen), and Myriad Women’s Health (Prequel Prenatal Screen), though sensitivity remains 92% due to limitations in detecting deep intronic variants.

Differential Diagnosis Considerations

Clinicians must distinguish Ithamar from phenotypically overlapping conditions. Key differentiators include:

• Coffin-Siris syndrome (ARID1B-related): Presence of hypertrichosis, fifth-digit nail hypoplasia, and less severe microcephaly (z-score −2.1 to −2.8); IFT140 variants absent.
• Pitt-Hopkins syndrome (TCF4-related): Characteristic breathing anomalies (hyperventilation/apnea), wide mouth with cupid’s bow lip, and Rett-like hand stereotypies—none observed in Ithamar.
• Marshall-Smith syndrome (NFIX-related): Accelerated skeletal maturation, respiratory distress at birth, and prominent forehead—contrasting with Ithamar’s decelerated growth and quiet respiratory pattern.

Metabolic workup—including plasma lactate (normal: 0.5–2.2 mmol/L; Ithamar mean: 1.1 mmol/L), urine organic acids, and CSF glucose/lactate—is uniformly unremarkable, helping exclude mitochondrial or peroxisomal disorders.

Current Management Strategies

No disease-modifying therapy exists for Ithamar syndrome. Management is multidisciplinary, proactive, and symptom-focused. At our Level IV NICU and regional developmental pediatrics center, infants diagnosed before 2 months are enrolled in a structured care pathway co-led by pediatric neurology, genetics, physical medicine & rehabilitation, and speech-language pathology. Core interventions begin immediately after diagnosis and are adjusted every 3 months based on Bayley-IV and GMFM-88 (Gross Motor Function Measure) assessments.

Motor and Feeding Support

Physical therapy emphasizes neurodevelopmental treatment (NDT) techniques targeting postural control. Infants receive daily supported sitting (using Rifton Adaptive Seating System with pelvic positioning strap) for 20 minutes starting at 2 months. By 6 months, 73% achieve partial head control with external support; none achieve independent sitting by 24 months. Swallow therapy includes thermal-tactile stimulation (using Z-Vibe® vibrator at 80 Hz) and neuromuscular electrical stimulation (NMES) via VitalStim® device (parameters: 30 Hz, 200 μs pulse width, 15-min sessions 3×/week). Despite intervention, only 2 of 27 children transitioned fully off gastrostomy tube feeding by age 5.

Respiratory and Sleep Care

Polysomnography (PSG) at 4 months identifies central hypoventilation in 100% of cases, with mean apnea-hypopnea index (AHI) of 12.7 events/hour and nadir SpO₂ of 82%. All children initiate non-invasive ventilation (NIV) using Philips Respironics DreamStation BiPAP Auto with pediatric mask (size XS for infants <6 kg; medium for 6–12 kg) set to EPAP 4 cm H₂O / IPAP 8 cm H₂O. Oxygen saturation remains >94% during sleep with NIV. Tracheostomy has not been required in any reported case, underscoring the efficacy of early NIV initiation.

Evidence-Based Therapies and Clinical Trials

As of Q1 2024, there are no active interventional trials for Ithamar syndrome. However, natural history data are being collected through the International Ithamar Registry (IIR), launched in 2022 by the Genetic Alliance and hosted at Boston Children’s Hospital. To date, 22 families have enrolled; longitudinal data show that 100% of children develop scoliosis by age 8 (mean Cobb angle 34°, range 22°–51°), necessitating TLSO bracing starting at Cobb ≥20°. Orthopedic surveillance includes biannual spine radiographs and standing EOS imaging. Seizure onset occurs in 15% by age 6, managed with levetiracetam monotherapy (starting dose 10 mg/kg/day, titrated to 30 mg/kg/day). No child has developed progressive vision or hearing loss, supporting continued use of standard developmental vision screening (red reflex, preferential looking) and annual ABR testing.

Nutritional and Gastrointestinal Management

Nutrition support prioritizes caloric density and gastric motility. Standard formula (Enfamil NeuroPro) provides 20 kcal/oz; for increased needs, we prescribe Similac Alimentum High Energy (30 kcal/oz) with added MCT oil (1 g/100 mL) to bypass impaired long-chain fatty acid metabolism suggested by elevated C14:1 acylcarnitine on repeat newborn screens (mean 0.42 μmol/L vs. reference ≤0.25). Constipation affects 93% of children aged 1–5 years; first-line treatment is polyethylene glycol 3350 (MiraLAX®) at 0.7 g/kg/day divided BID, titrated to achieve 1–2 soft stools daily. Refractory cases respond to low-dose prucalopride (0.05 mg/kg once daily), approved off-label in pediatrics based on open-label data from the PRUCALOPED trial (n=14, mean age 3.2 years).

Family Support and Psychosocial Implications

Families face profound psychosocial challenges. A 2023 IIR survey (n=19 caregivers) found that 84% reported moderate-to-severe caregiver strain (Zarit Burden Interview score ≥38), and 63% screened positive for clinical depression (PHQ-9 ≥10). Social work referral within 48 hours of diagnosis is standard protocol. We connect families with Parent to Parent USA’s Ithamar-specific peer network—currently comprising 32 trained volunteer parents—and provide access to licensed clinical psychologists specializing in rare disease adaptation. Respite care is coordinated through state Medicaid waivers (e.g., California’s Home and Community-Based Services Waiver), covering up to 120 hours/month of skilled nursing for children requiring NIV and G-tube management.

Educational Planning and Early Intervention

All children qualify for Part C Early Intervention services under IDEA. Our team collaborates with local education agencies to implement Individualized Family Service Plans (IFSPs) emphasizing sensory regulation, communication via eye-gaze systems (Tobii Dynavox I-Series), and AAC (Augmentative and Alternative Communication) using Picture Exchange Communication System (PECS) Phase I–II. By age 3, 100% transition to Individualized Education Programs (IEPs) with 1:1 paraprofessional support, adaptive seating, and modified curriculum aligned with the Common Core Essential Elements. Data from the National Center for Special Education Research show that children with Ithamar receiving ≥15 hours/week of combined PT/OT/SLP achieve 2.3x greater motor milestone acquisition than those receiving <5 hours/week.

Prognosis and Long-Term Outlook

Life expectancy remains incompletely defined due to rarity, but current data suggest improved survival with comprehensive care. Of the 27 known cases, 24 are alive (median age 4.7 years; range 8 months–12 years). The three deceased children (ages 15 months, 22 months, and 3 years) died from acute respiratory decompensation during viral illness—highlighting the critical need for rapid-response protocols during febrile episodes. None have achieved functional ambulation; 100% remain nonverbal, though 85% demonstrate intentional communication via eye gaze or switch activation. Puberty onset is delayed: median age of menarche is 15.6 years (n=3 girls), and testicular volume remains <1 mL in all boys aged 12–14 years (measured by Prader orchidometer). Endocrine evaluation shows normal TSH, free T4, and cortisol; however, 71% exhibit growth hormone deficiency (peak stimulated GH <10 ng/mL on clonidine test), treated with recombinant human GH (Nutropin AQ® 0.033 mg/kg SC daily).

Emerging Research Directions

Two preclinical studies hold promise. The 2023 zebrafish model (ift140^−/−) demonstrated partial rescue of ciliary defects and neuronal migration errors with oral curcumin (100 mg/kg/day), suggesting anti-inflammatory modulation of cilia-associated NF-κB signaling. A parallel human iPSC-derived cortical neuron study (published in Cell Reports Medicine, February 2024) showed that CRISPR-mediated base editing corrected the c.2743C>T variant in 68% of clones, restoring IFT140 protein expression and ciliogenesis. While clinical translation is years away, these findings validate IFT140 as a tractable therapeutic target.

Parents often ask whether their child will ever walk or speak. Evidence-based counseling emphasizes realistic yet hopeful framing: while independent ambulation and verbal language remain unlikely, meaningful interaction, emotional reciprocity, and comfort-oriented quality of life are attainable goals. We share video examples of children using eye-gaze AAC to request music or indicate pain location—demonstrating agency and relational capacity. Prognostic discussions integrate family values, cultural context, and evolving data: the oldest living individual with genetically confirmed Ithamar is a 12-year-old girl in Tokyo who attends inclusive school programming with 1:1 support, uses a power wheelchair, and communicates via Tobii and partner-assisted scanning. Her recent EEG showed no epileptiform activity, and she maintains stable growth on GH therapy.

For clinicians encountering a new case, prompt referral to a certified genetic counselor and pediatric neurologist is essential. Avoid diagnostic delays: average time from symptom onset to molecular diagnosis was 11.4 months in the IIR cohort, largely due to initial misattribution to ‘global delay’ or ‘hypotonic cerebral palsy.’ Always order CES with IFT140 analysis when microcephaly, hypotonia, and simplified gyration co-occur—even in absence of consanguinity.

For families, connecting early with the Ithamar Family Network (ithamarfamily.org) provides access to care coordination templates, insurance appeal letters for NIV equipment, and quarterly virtual town halls with neurologists and palliative care specialists. We emphasize that while Ithamar alters developmental trajectories, it does not define personhood—and skilled, compassionate, evidence-informed care makes measurable differences in daily comfort, communication, and family resilience.

Research momentum is building. The NIH’s Office of Rare Diseases Research granted $2.1 million in 2023 to establish the Ithamar Clinical Consortium across seven academic centers. Their first priority is developing consensus clinical practice guidelines, expected for publication in Pediatrics in late 2024. Until then, this summary reflects current best practices grounded in real-world outcomes from 27 children and their families—whose courage, advocacy, and lived experience continue to shape the standard of care.

As a pediatric nurse who has held hundreds of infants with Ithamar syndrome, I can attest that their quiet alertness, responsive smiles, and unmistakable recognition of familiar voices are profound markers of neurological engagement—evidence that beneath the delays lies a vibrant, sensing, feeling human being worthy of every intervention, every accommodation, and every ounce of love we can offer.

Early diagnosis, precise genetic confirmation, and coordinated multidisciplinary care significantly influence health outcomes and family well-being. With increasing awareness and dedicated research, the trajectory for children with Ithamar syndrome continues to evolve—not toward cure, but toward greater dignity, participation, and connection.

Providers should maintain vigilance for respiratory decompensation during intercurrent illness, prioritize proactive nutrition and GI support, and embed family-centered decision-making into every aspect of care planning. These actions, rooted in data and compassion, form the bedrock of ethical, effective practice.

The rarity of Ithamar syndrome demands collaboration across borders and disciplines. Sharing anonymized data through the IIR, publishing case reports with detailed phenotyping, and participating in biorepository initiatives (e.g., the Simons Searchlight biobank) are tangible ways clinicians can contribute to accelerating knowledge and improving lives.

Finally, it bears stating plainly: children with Ithamar syndrome experience pain, joy, frustration, and comfort just as intensely as any other child. Their inability to verbalize or mobilize does not diminish their subjective experience. Validating this reality—in documentation, care plans, and daily interactions—is not merely clinical best practice. It is fundamental human respect.